Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2016 | Ethical considerations of biomarker use in prodromal Alzheimer’s disease

Giovanni Frisoni • 29 May 2016
EAN 2016
Alzheimer’s Disease

There are currently no approved preventive or disease-modifying therapies available for Alzheimer’s disease. At the 2nd Congress of the European Academy of Neurology (EAN), held in Copenhagen, Denmark, from May 28–31 2016, Giovanni Frisoni, MD, from Geneva University Hospital, Geneva, Switzerland, discusses some of the ethical challenges associated with assessing biomarker status that may indicate Alzheimer’s disease at an early stage.

More from Giovanni Frisoni

Best outcome measures for Alzheimer’s disease follow-up in the clinic
1:56
Best outcome measures for Alzheimer’s disease follow-up in the clinic
Giovanni Frisoni • 30 Mar 2023
Exploring the potential role of amyloid deposition in the gut in Alzheimer's disease
1:36
Exploring the potential role of amyloid deposition in the gut in Alzheimer's disease
Giovanni Frisoni • 30 Mar 2023
Defining subgroups of patients with subjective cognitive decline more likely to progress
4:20
Defining subgroups of patients with subjective cognitive decline more likely to progress
Giovanni Frisoni • 30 Mar 2023
European task force recommendations: shifting memory clinics towards prevention
4:51
European task force recommendations: shifting memory clinics towards prevention
Giovanni Frisoni • 30 Mar 2023

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
MenoCog: risk and protective factors for cognitive function in the menopause transition
2:37
MenoCog: risk and protective factors for cognitive function in the menopause transition
Amber Watts • 14 Jul 2026
What are the biological mechanisms underlying the higher prevalence of AD in women?
1:55
What are the biological mechanisms underlying the higher prevalence of AD in women?
Amber Watts • 14 Jul 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals